Lv7
3384 积分 2021-02-05 加入
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
1个月前
已完结
The VIVID-1 study: A novel methodological approach provides further evidence of efficacy of selective IL-23 inhibition in Crohn’s disease
1个月前
已完结
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
1个月前
已完结
Network meta‐analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease
1个月前
已完结
我国克罗恩病不同年代发病率及患病率的比较
3个月前
已完结
中国大陆地区克罗恩病50年报道资料的系统分析
3个月前
已完结
基于2013年～2017年我国城镇职工健康医疗保险数据库的克罗恩病患病率及变化趋势研究
3个月前
已完结
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
3个月前
已完结
Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
3个月前
已完结
Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis
3个月前
已完结
皖公网安备34019202002308
